Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007 (Q56880134)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007	article

Statements

scholarly article

0 references

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007 (English)

0 references

World Health Organization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Albert Osterhaus

2

0 references

Marie Paule Kieny

5

object named as

Marie Paule Kieny

0 references

author name string

Marc P. Girard

1

0 references

Yuri Pervikov

3

0 references

Laszlo Palkonyay

4

0 references

language of work or name

0 references

publication date

May 2008

0 references

0 references

26

0 references

20

0 references

2443-2450

0 references

Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Induction of heterosubtypic immunity to influenza virus by intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Sublingual vaccination with influenza virus protects mice against lethal viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Antibody responses after dose-sparing intradermal influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Serum antibody responses after intradermal vaccination against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Dose sparing with intradermal injection of influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Universal influenza A vaccine: optimization of M2-based constructs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.006

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.03.006

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56880134&oldid=1829597998"